ctDNA-based molecular residual disease and survival in resectable colorectal cancer
Nakamura, et al. Nature Medicine 2024
Read Publication
Nakamura, et al. Nature Medicine 2024
Read Publication
Read Article
Discover how Renasight can provide valuable information about your kindey health.
Read More
Learn about Renasight genetic testing and how it can provide valuable information for patient management of kidney disease.
Read More
Have a question or comment?
Contact UsHear from our ProActive Study Investigator In this episode of our Inside the ProActive Study Podcast, Dr. Yasir Qazi talks to us about: • His dd-cfDNA “surveillance journey” and protocol development.
Watch Video
Hear from our ProActive Study Investigator In this episode of our Inside the ProActive Study Podcast, Dr. Yasir Qazi talks to us about his dd-cfDNA “surveillance journey” and protocol development.
Listen Now
In this episode of our Inside the ProActive Study Podcast, Dr. Matthew Cooper shares his insights on: • Utilizing cfDNA alongside DSA and biopsies before implementing his dd-cfDNA surveillance protoc
Watch Video
In this episode of our Inside the ProActive Study Podcast, Dr. Matthew Cooper shares his insights on: • Utilizing cfDNA alongside DSA and biopsies before implementing his dd-cfDNA surveillance...
Listen Now
In this episode of our Inside the ProActive Study Podcast, Dr. Millie Samaniego-Picota tells us about: • Her experience expanding the ProActive Study Protocol schedule to all her patients • How her
Watch Video
In this episode of our Inside the ProActive Study Podcast, Dr. Millie Samaniego-Picota tells us about: • Her experience expanding the ProActive Study Protocol schedule to all her patients • How her
Listen Now
Watch Video
Listen Now
Watch Video
Listen Now
Watch Video
Listen Now
Watch Video
Watch Video
Watch Video
Learn how the addition of DQS significantly reduces the rate of false positive results and improves the accuracy of detecting both acute cellular rejection (ACR) and antibody mediated rejection (AMR).
Watch Video
Dr. Sam Leonard, Sr. Medical Director (Natera), walks through how to appropriately consider the balance between high detection rates and screen positive rates when selecting a screen.
Watch Video
Dr. Blagowidow, OB Geneticist, talks about the importance of early prenatal 22q11.2 deletion syndrome (22q, formerly DiGeorge syndrome) screening and factors to consider when selecting a screen.
Watch Video
Watch Video
Watch Video
Have a question or comment?
Contact UsWatch Video
Read More
Read More
Read More
Watch Video
Read More
Watch Video
ctDNA for Molecular Residual Disease (MRD) Detection & New Tools for Improved Hereditary Cancer Testing Uptake
Watch Video
Read More
During this webinar, we will review the newest recommendations from NKF, KDIGO, and NEJM on genetic testing for CKD and learn how genetic testing impacts the diagnosis and management of kidney disease
Watch Video
Read More
Being Proactive with Prospera on Their Transplant Care
Watch Video
Loading More...